WO2001051628A3 - Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - Google Patents

Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer Download PDF

Info

Publication number
WO2001051628A3
WO2001051628A3 PCT/US2001/000798 US0100798W WO0151628A3 WO 2001051628 A3 WO2001051628 A3 WO 2001051628A3 US 0100798 W US0100798 W US 0100798W WO 0151628 A3 WO0151628 A3 WO 0151628A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
methods
breast cancer
assessment
therapy
Prior art date
Application number
PCT/US2001/000798
Other languages
French (fr)
Other versions
WO2001051628A2 (en
WO2001051628A9 (en
Inventor
James Lillie
Yongyao Xu
Youzhen Wang
Kathleen Steinmann
Original Assignee
Millenium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millenium Pharmaceuticals Inc filed Critical Millenium Pharmaceuticals Inc
Priority to AU2001229340A priority Critical patent/AU2001229340A1/en
Publication of WO2001051628A2 publication Critical patent/WO2001051628A2/en
Publication of WO2001051628A3 publication Critical patent/WO2001051628A3/en
Publication of WO2001051628A9 publication Critical patent/WO2001051628A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
PCT/US2001/000798 2000-01-14 2001-01-10 Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer WO2001051628A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001229340A AU2001229340A1 (en) 2000-01-14 2001-01-10 Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US17607700P 2000-01-14 2000-01-14
US60/176,077 2000-01-14
US18916700P 2000-03-14 2000-03-14
US60/189,167 2000-03-14
US19209900P 2000-03-24 2000-03-24
US60/192,099 2000-03-24
US19348000P 2000-03-29 2000-03-29
US60/193,480 2000-03-29
US20523000P 2000-05-15 2000-05-15
US60/205,230 2000-05-15
US21131500P 2000-06-09 2000-06-09
US60/211,315 2000-06-09
US22053400P 2000-07-25 2000-07-25
US60/220,534 2000-07-25

Publications (3)

Publication Number Publication Date
WO2001051628A2 WO2001051628A2 (en) 2001-07-19
WO2001051628A3 true WO2001051628A3 (en) 2002-04-25
WO2001051628A9 WO2001051628A9 (en) 2003-07-17

Family

ID=27569146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000798 WO2001051628A2 (en) 2000-01-14 2001-01-10 Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Country Status (2)

Country Link
AU (1) AU2001229340A1 (en)
WO (1) WO2001051628A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
ES2304126T3 (en) 2000-01-26 2008-09-16 Agensys, Inc. 84P2A9: A SPECIFIC PROTEIN OF PROSTATE AND TESTICLES HIGHLY EXPRESSED IN CANCER DE PROSTATA.
US20020119466A1 (en) * 2000-08-24 2002-08-29 Rachel Meyers 46863, a novel human methyltransferase and uses thereof
AU2001263796A1 (en) * 2000-03-22 2001-10-03 Bayer Aktiengesellschaft Regulation of human latrophilin-like g protein-coupled receptor
WO2002006326A2 (en) * 2000-07-14 2002-01-24 Millennium Pharmaceuticals, Inc. 62088, a human nucleoside phosphatase family member and uses thereof
WO2002016598A2 (en) 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2001294684A1 (en) * 2000-09-29 2002-04-08 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
EP1332214B1 (en) * 2000-10-05 2009-11-18 Millenium Pharmaceuticals, Inc. 32144, a human fatty acid amide hydrolase and uses thereof
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002083928A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
EP1385962A2 (en) * 2001-05-02 2004-02-04 Bayer HealthCare AG Human prolyl 4-hydroxylases
WO2002103320A2 (en) 2001-06-18 2002-12-27 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP2003250550A (en) * 2002-02-25 2003-09-09 Nissui Pharm Co Ltd Fat cell differentiation-related gene and protein
DE10211088A1 (en) * 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003255459A1 (en) * 2002-08-19 2004-03-11 Bayer Healthcare Ag Regulation of human secretin-type gpcr (latrophilin)
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
ATE528397T1 (en) 2003-08-08 2011-10-15 Perseus Proteomics Inc GENE OVEREXPRESSED IN CANCER
ES2303390B1 (en) * 2003-09-24 2009-08-17 Progenika Biopharma, S.A. METHODS FOR IN VITRO AND IN VITRO DIAGNOSIS OF THE DUCTAL PANCREAS ADENOCARCINOMA AND / OR OF A PANCREATITIS; AND FOR THE DEVELOPMENT OF PHARMACS AGAINST DUCTAL PANCREAS ADENOCARCINOMA AND / OR AGAINST A PANCREATITIS.
WO2005090564A1 (en) * 2004-03-19 2005-09-29 Genomidea Inc. Gene promoting vascular endothelial cell growth
NZ556158A (en) * 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
FR2892730A1 (en) * 2005-10-28 2007-05-04 Biomerieux Sa Detecting the presence/risk of cancer development in a mammal, comprises detecting the presence/absence or (relative) quantity e.g. of nucleic acids and/or polypeptides coded by the nucleic acids, which indicates the presence/risk
JP2007267692A (en) * 2006-03-31 2007-10-18 Sysmex Corp Metastasis marker for lymph node and primer for breast cancer and method for judging lymph node metastasis of breast cancer using the same marker
EP2621526B1 (en) 2010-09-29 2018-06-06 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US10829772B2 (en) 2012-06-22 2020-11-10 Monsanto Technology Llc Unique modular vector design
TR201900694T4 (en) 2012-08-23 2019-02-21 Agensys Inc Antibody drug conjugates (ADC) that bind to 158p1d7 proteins.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROWN M A ET AL: "PHYSICAL MAPPING, CLONING, AND IDENTIFICATION OF GENES WITHIN A 500-KB REGION CONTAINING BRCA1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, 1 May 1995 (1995-05-01), pages 4362 - 4366, XP002017873, ISSN: 0027-8424 *
DATABASE EMBL 11 May 1999 (1999-05-11), MARRA M ET AL: "uk22d10.y1 Sugano mouse embryo mewa Mus musculus cDNA clone", XP002175764 *
DATABASE EMBL 28 October 1999 (1999-10-28), BIRREN B ET AL: "Homo sapiens clone RP11-2L5", XP002175765 *
JI H ET AL: "IDENTIFICATION OF A BREAST CANCER-SPECIFIC GENE, BCSG1, BY DIRECT DIFFERENTIAL CDNA SEQUENCING", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 4, 15 February 1997 (1997-02-15), pages 759 - 764, XP002065403, ISSN: 0008-5472 *
WOOSTER R ET AL: "IDENTIFICATION OF THE BREAST CANCER SUSCEPTIBILITY GENE BRCA2", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 378, 1 December 1995 (1995-12-01), pages 789 - 792, XP002029512, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2001051628A2 (en) 2001-07-19
WO2001051628A9 (en) 2003-07-17
AU2001229340A1 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2003060465A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2004061423A3 (en) Compositions and methods for diagnosing and treating colon cancers
WO2005032328A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2002085298A3 (en) Method for detecting breast cancer cells
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2002044360A3 (en) Modified arginine deiminase
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: TABLES 3 AND 4, SEQUENCE LISTING REPLACED BY CORRECT TABLES 3 AND 4; DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

NENP Non-entry into the national phase

Ref country code: JP